5TH WORLD CONGRESS OF CUTANEOUS LYMPHOMAS OVERVIEW
Cutaneous lymphomas are a heterogeneous group of rare, but potentially life-threatening, lymphomas affecting about 4,000 new patients annually in the U.S. alone. The disease is chronic and severely debilitating with no curative therapies currently available, hereby affecting patients' and caregivers' quality of life. The patients are managed by dermatologists, hematologists/oncologists, radiation oncologists and others with limited communication among these specialists, which poses additional management challenges.
There are gaps in understanding the biology of tumor cells and the supporting tumor microenvironment and how these translate into clinical management. In addition, there are novel immune-based and cellular therapies developed, however, it is not clear how to optimize these therapies for cutaneous lymphoma patients. This conference will provide the platform to improve understanding of the various aspects of these disorders, such as the evaluation of novel biomarkers, incorporating this into patient care or assessment of biopsies to facilitate diagnosis, and for treatment paradigms as well as assessment of quality-of-life tools and patient-reported outcomes in clinical care and practice.
THIS INTENSIVE PROGRAM WILL PROVIDE PARTICIPANTS WITH AN ENHANCED ABILITY TO DIAGNOSE, INTERPRET AND APPLY BEST TREATMENT OPTIONS FOR CUTANEOUS LYMPHOMAS.
- Lectures and scientific abstracts on pathology, genetics, tumor microenvironment, therapeutics, clinical studies, quality of life, and leading-edge research in cutaneous lymphomas
- Debates and discussions on key controversies
- Interactive question and answer sessions
- Poster sessions
- Networking opportunities among clinicians, investigators and scientists across institutions and geographical borders
The Scientific Committee invites you to submit your abstracts in this field for oral and poster consideration. Abstract acceptance will be driven by scientific merit, where only the best submissions will be selected.
The committee encourages experts in this field to submit their scientific work and contribute to making this the best meeting yet!
ABSTRACTS FOCUS AREAS INCLUDE
- Classification/Epidemiology/Prognostic Factors
- Cutaneous Lymphoma International Consortium – PROCLIPI Studies
- Biologic Insights
- Tumor Microenvironment
- Therapeutics/Preclinical Studies
- Quality of Life/Patient-Reported Outcomes
- Challenging Cases of Cutaneous Lymphomas
- Leading-Edge Research and Future Directions of Cutaneous Lymphomas
SUBMISSION DEADLINE: NOVEMBER 15, 2023
Physicians (clinicians & pathologists), advanced practice providers, other health care providers, researchers, scientists, students, trainees (residents, fellows), patients, patient caregivers, and others with interest in cutaneous lymphomas.
- Integrate novel immunophenotypic and molecular markers to facilitate diagnosis.
- Evaluate the safety and efficacy of current and emerging therapeutic approaches for patients with cutaneous lymphoma.
- Assess trends in precision medicine and treatment paradigms in cutaneous lymphoma.
- Utilize patient-reported outcomes and disease-specific factors that may impact treatment decisions in cutaneous lymphoma.
- Discuss the latest discoveries in cutaneous lymphoma.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this live activity for a maximum of 19.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
WILL YOU JOIN US FOR THE
5TH WORLD CONGRESS OF CUTANEOUS LYMPHOMAS?
APRIL 11 TO 13, 2024
PASADENA CONVENTION CENTER | PASADENA, CA, USA
FOR MORE INFORMATION
Please contact the Department of Continuing Medical Education at email@example.com.